Raltegravir tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency ...

600 mg of Merck Sharp & Dohme LLC. Lupin is the exclusive first-to-file for this product and may be eligible to receive a 180 ...

Sotatercept is the first activin signaling inhibitor therapy for PAH in Canada, a new class of therapy that works by improving the balance between pro-proliferative and anti-proliferative signaling to ...

Lupin receives US FDA tentative approval for raltegravir tablets, USP: Our Bureau, Mumbai Friday, November 8, 2024, 17:45 Hrs [IST] Global pharma major Lupin Limited (Lupin) annou ...

Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of ...